Another emerging HER2 status, HER2-ultralow breast cancer contains even fewer HER2 proteins than HER2-low and HER2-positive breast cancers. Currently, HER2-ultralow breast cancers have an immunohistochemistry (IHC) test score of 0 with HER2-positive staining in up to 10 percent of tumor cells. This status only has implications for patients with metastatic breast cancer and is not part of a routine pathology report.
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Stay in the know with the latest research news, insights, and resources delivered to your inbox.
Follow BCRF on all the major platforms for research news, inspiring stories, and more.
